pSivida Signs Drug Delivery Licensing Agreement with Faber Research LLC

pSivida also begins licensing negotiations with large global pharma

BOSTON & PERTH, Australia--(BUSINESS WIRE)--Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced it has entered into a licensing agreement with US-based Faber Research LLC (Faber) to develop pSividas proprietary Durasert, Zanisert and Co-Drug drug delivery technologies for infectious diseases and diseases of the ear.

“We believe this represents a significant opportunity for our drug delivery technologies to be exploited in another therapeutic area - that of infectious diseases and it will be done at no direct cost to us.”

This announcement follows an announcement on December 26, 2006 that pSivida entered into an exclusive negotiation period with a major global pharmaceutical company to acquire a worldwide, royalty bearing license to make, use and sell products using pSividas drug delivery technologies. The pharmaceutical company will make payments totalling US$990k (AU$1.3m) to pSivida for the right to exclusively negotiate a licensing agreement with the Company for a period of three months and to fund the cost of a preclinical study. The commencement of licensing negotiations follows a 12 month evaluation of pSivida's technologies by the large global pharmaceutical company.

Under the terms of the Faber license, Faber receives exclusive rights to pSividas technologies for diseases of the ear and for five specific infectious diseases, namely malaria, HIV/AIDS, influenza, tuberculosis, and osteomyelitis. All costs of development will be born by Faber and its operating company Auritec Pharmaceuticals Inc (Auritec) and pSivida will receive royalties and milestone payments.

In addition, pSivida has granted Faber co-exclusive rights to the Durasert, Zanisert and Co-Drug drug delivery technologies for other infectious diseases. Under this arrangement pSivida and Faber can elect to convert their co-exclusive rights to exclusive rights for a specific infectious disease indication(s). pSivida believes this maximizes the potential to commercialize these technologies in the development of novel anti-infective drugs, a market that reached (a)US$44 billion in 2005.

pSividas Durasert controlled release technology is already validated in that it forms the basis of the companys ophthalmic drug delivery products, Retisert, which is FDA approved, and Medidur, which is currently in Phase III clinical trials.

Auritec has developed novel approaches to extended release drug delivery with implications for indications including: HIV microbicides, the treatment of malaria and the prevention of pandemic influenza. Auritec also has an active program for the delivery of drugs to the inner ear.

Dr. Roger Brimblecombe, Chairman and CEO at pSivida said, We believe this represents a significant opportunity for our drug delivery technologies to be exploited in another therapeutic area - that of infectious diseases and it will be done at no direct cost to us.

Dr. Thomas J Smith, MD, Chairman and Chief Executive Officer at Auritec said, We look forward to the opportunities for synergies between our companies in the treatment of infectious diseases.

Dr William H. Slattery, MD, Clinical Professor of Otolaryngology at the University of Southern California, and Director of Otology Research at Auritec said, The ability to utilize pSividas drug delivery technologies will accelerate our otology program significantly.

Faber Research LLC and Auritec Pharmaceuticals

Faber is the intellectual property holding company for Auritec, a private company based in Pasadena, California, specializing in innovative, extended release drug delivery systems. Auritec was co-founded by Dr. Thomas J Smith, MD, who was previously Chairman and co-founder of Control Delivery Systems, Inc., the Boston, MA. based drug delivery company pSivida acquired in January 2006.

(a) CHA Advances Reports, 2006

NOTES TO EDITORS:

pSivida is a global bio-nanotech company committed to the biomedical sector and the development of drug delivery products. pSivida has developed proprietary drug delivery technology which it had previously referred to as its AEON technology. pSivida now has identified two somewhat distinct avenues for such technology: non-biodegradable implants for focused drug delivery (Durasert) and biodegradable implants for focused drug delivery (Zanisert).

Retisert is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb own the trademarks Vitrasert® and Retisert. pSivida has licensed the technologies underlying both of these products to Bausch & Lomb. The technology underlying Medidur for diabetic macular edema is licensed to Alimera Sciences and is in Phase III clinical trials.

pSivida owns the rights to develop and commercialize a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon, which has applications in drug delivery, wound healing, orthopedics, and tissue engineering. pSividas subsidiary, AION Diagnostics Limited is developing diagnostic products and the subsidiary pSiNutria is developing food technology products both using BioSilicon.

pSividas intellectual property portfolio consists of 76 patent families, 95 granted patents, including patents accepted for issuance, and over 300 patent applications. pSivida conducts its operations from offices and facilities near Boston in the United States, Malvern in the United Kingdom, Perth in Australia and Singapore.

pSivida is listed on NASDAQ (PSDV), the Australian Stock Exchange (PSD) and on the Frankfurt Stock Exchange on the XETRA system (German Symbol: PSI. Securities Code (WKN) 358705). pSivida is a founding member of the NASDAQ Health Care Index and the Merrill Lynch Nanotechnology Index.

This document contains forward-looking statements that involve risks and uncertainties including with respect to Fabers development of pSividas technologies for infectious diseases and disease of the ear; the major global pharmas acquiring a license to pSividas drug delivery technology; the potential signing of definitive agreements with Nordic on the terms described; the amount of pSividas portion of the costs to develop Medidur for DME; the potential size of certain markets; and potential products, applications and regulatory approvals. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors including:

The failure of Faber to develop pSividas drug delivery technologies for infectious diseases and diseases of the ear; failure of the election to convert co-exclusive rights to exclusive rights to maximize the potential to commercialize pSividas technologies in the development of novel anti-infective drugs; inability of any products developed under the license to Faber to penetrate the novel anti-infective drug market; failure of novel anti-infective drug market to continue to remain at US$44 billion; failure of Auritecs novel approaches to extended release drug delivery to have implications for indications including; HIV microbicides, the treatment of malaria and the prevention of pandemic influenza; failure of Auritec to continue its active program for the delivery of drugs to the inner ear; the failure of the company to successfully negotiate and sign a license agreement with the major global pharma on advantageous terms or at all; failure of the ongoing evaluation with the major global pharma to produce favorable results; failure of the focus of the preclinical study to be in a very significant product opportunity; failure of the company to successfully close the transaction with Nordic contemplated by the MOUs with Nordic; the failure of the Company to obtain the requisite shareholder approvals to complete the Nordic transactions; failure of pSividas share of Medidur development costs to be no more than US$22m; failure of the results of the Retisert for DME trial to be a good indicator of the results of pSividas ongoing Phase III Medidur for DME trial; failure of the Medidur trials in DME to show a very similar improvement in visual acuity and diabetic retinopathy severity score as Retisert for DME; failure of Medidur to release fluocinolone acetonide at the same rate as Retisert; our inability to recruit patients for the Phase III Medidur for DME trial; our inability to raise additional funds at favorable terms or any terms; our inability to repay the amended notes and new convertible notes; our inability to develop proposed products, including without limitation, in the drug delivery, wound healing, orthopaedics, and tissue engineering, diagnostics and food technology fields; failure of our evaluation agreements to produce favorable results and/or result in license agreements; failure to develop applications for BioSilicon due to regulatory, scientific or other issues; failure to complete negotiations for new centers for the BrachySil Phase IIb clinical trial for inoperable primary liver cancer; failure of our discussions with the FDA for BrachySil to continue or to lead to FDA approval; failure of the BrachySil Phase IIb clinical trial for inoperable primary liver cancer to determine the optimal dose, provide key safety data or support future pivotal efficacy trials or product registration or approval; failure of the BrachySil primary liver program that is in Phase IIb clinical trials to provide a valuable platform for the development and commercialization of BrachySil for pancreatic cancer and other indications; failure of the findings of the pancreatic cancer Phase IIa trial to provide a platform for further multicenter efficacy and safety trials; and failure of there to be optimization and standardization between our two pancreatic cancer study centers. Other reasons are contained in cautionary statements in the Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to update any oral or written forward-looking statements that may be made by or on behalf of pSivida.

Contacts

pSivida Limited
Brian Leedman, + 61 412 281 780
Director of Investor Relations
brianl@psivida.com
or
Martin E. Janis & Company, Inc
US Public Relations
Beverly Jedynak, 312-943-1100 ext. 12
President
bjedynak@janispr.com
or
Accent Marketing Limited
European Public Relations
Eva Reuter, +49 (254) 393 0740
e.reuter@e-reuter-ir.com
or
For Auritec
Auritec Pharmaceuticals
Gary Ransom, 626-376-4070
Vice-President Corporate Development
gransom@auriecpharma.com
www.auritecpharma.com
or
Oak Crest Institute of Science
US Public Relations
Sayuri D. Hanna, 626-817-0886
s.hanna@oak-crest.org

Better Be Business Wired.

Business Wire is the leading source for press releases, photos, multimedia and regulatory filings from companies and groups throughout the world.